Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07557615 · ClinicalTrials.gov registry record · Early Phase 1
hCG Treatment for Rehabilitation From a TBI
A Early Phase 1 study, sponsored by VA Office of Research and Development.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
NCT07557615: Clinical Trial Early Phase 1 study, sponsored by VA Office of Research and Development.
NCT07557615 is a Early Phase 1 study that has not yet begun recruiting, run by VA Office of Research and Development. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07557615, a Early Phase 1 study, has not yet begun recruiting, sponsored by VA Office of Research and Development.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The COGNI-REHAB Trial is a single-site, phase O/I, randomized, double-blind, placebo-controlled study of human chorionic gonadotropin (hCG; choriogonadotropin alfa, Ovidrel®) in men with post-acute, moderate to severe traumatic brain injury (msTBI). Its objective is to assess the safety and efficacy of a 24-week regimen of Ovidrel (125 micrograms twice weekly) compared to placebo on treatment-emergent adverse events (TEAEs), cognitive and functional recovery, and circulating sex hormones.
Interventions
- OTHER Placebo
- DRUG Ovidrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-10-01 |
| Est. Completion | 2029-09-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07557615
The ClinicalTrials.gov registry entry for NCT07557615 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07557615 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07557615 about?
NCT07557615 is a clinical study titled "hCG Treatment for Rehabilitation From a TBI". The COGNI-REHAB Trial is a single-site, phase O/I, randomized, double-blind, placebo-controlled study of human chorionic gonadotropin (hCG; choriogonadotropin alfa, Ovidrel®) in men with post-acute, moderate to severe traumatic brain injury (msTBI). Its objective is to assess the safety and efficacy...
What is the current status of trial NCT07557615?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2026-10-01. Estimated completion is 2029-09-30.
What interventions are being tested in trial NCT07557615?
The interventions under investigation include: Placebo (OTHER), Ovidrel (DRUG).
Who is sponsoring clinical trial NCT07557615?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.